Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis
Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to co...
Saved in:
| Published in | Antimicrobial agents and chemotherapy Vol. 45; no. 11; pp. 3092 - 3097 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.11.2001
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Deltalog(10) CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C(max)/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF. |
|---|---|
| AbstractList | Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Deltalog(10) CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C(max)/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF. Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration (C(max)) values were 1.8, 4.2, and 4.9 microg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 microg/ml x h, respectively, and the half-life values (t(1/2)) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Deltalog(10) CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were -5.70, -6.62, and -7.02; -7.37, -7.37, and -6.87; and -6.62, -6.62, and -6.62, respectively, whereas those of ceftriaxone and meropenem were -4.18, -5.24, and -4.43, and -3.64, -3.59, and -4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C(max)/MBC were interrelated (r = 0.81); there was less correlation with T > MBC (r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF. ABSTRACT Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration ( C max ) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values ( t ½ ) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog 10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were −5.70, −6.62, and −7.02; −7.37, −7.37, and −6.87; and −6.62, −6.62, and −6.62, respectively, whereas those of ceftriaxone and meropenem were −4.18, −5.24, and −4.43, and −3.64, −3.59, and −4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C max /MBC were interrelated ( r = 0.81); there was less correlation with T > MBC ( r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF. Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this study were to evaluate the bactericidal effectiveness and the pharmacodynamic profile of moxifloxacin in cerebrospinal fluid (CSF) and to compare the bactericidal activity with that of ceftriaxone and meropenem therapy. After induction of meningitis, animals were given single doses of 10, 20, and 40 mg/kg or divided-dose regimens of 5, 10, and 20 mg/kg twice, separated by 6 h. After single doses, the penetration of moxifloxacin into purulent CSF, measured as percentage of the area under the concentration-time curve (AUC) in CSF relative to the AUC in plasma, was approximately 50%. After single doses of 10, 20, and 40 mg/kg, the maximum CSF concentration ( C max ) values were 1.8, 4.2, and 4.9 μg/ml, respectively; the AUC values (total drug) were 13.4, 25.4, and 27.1 μg/ml · h, respectively, and the half-life values ( t ½ ) were 6.7, 6.6, and 4.7 h, respectively. The bacterial killing in CSF for moxifloxacin, calculated as the Δlog 10 CFU per milliliter per hour, at 3, 6, and 12 h after single doses of 10, 20, and 40 mg/kg were −5.70, −6.62, and −7.02; −7.37, −7.37, and −6.87; and −6.62, −6.62, and −6.62, respectively, whereas those of ceftriaxone and meropenem were −4.18, −5.24, and −4.43, and −3.64, −3.59, and −4.12, respectively. The CSF pharmacodynamic indices of AUC/MBC and C max /MBC were interrelated ( r = 0.81); there was less correlation with T > MBC ( r = 0.74). In this model, therapy with moxifloxacin appears to be at least as effective as ceftriaxone and more effective than meropenem therapy in eradicating E. coli from CSF. |
| Author | MCCOIG, Cynthia C MICHELOW, Ian C PATEL, Chetan JAFRI, Hasan S HARDY, Robert D GHAFFAR, Faryal RODRIGUEZ-CERRATO, Violeta OLSEN, Kurt MCCRACKEN, George H |
| AuthorAffiliation | Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063 |
| AuthorAffiliation_xml | – name: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063 |
| Author_xml | – sequence: 1 givenname: Violeta surname: RODRIGUEZ-CERRATO fullname: RODRIGUEZ-CERRATO, Violeta organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 2 givenname: Cynthia C surname: MCCOIG fullname: MCCOIG, Cynthia C organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 3 givenname: Ian C surname: MICHELOW fullname: MICHELOW, Ian C organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 4 givenname: Faryal surname: GHAFFAR fullname: GHAFFAR, Faryal organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 5 givenname: Hasan S surname: JAFRI fullname: JAFRI, Hasan S organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 6 givenname: Robert D surname: HARDY fullname: HARDY, Robert D organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 7 givenname: Chetan surname: PATEL fullname: PATEL, Chetan organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 8 givenname: Kurt surname: OLSEN fullname: OLSEN, Kurt organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States – sequence: 9 givenname: George H surname: MCCRACKEN fullname: MCCRACKEN, George H organization: Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9063, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14071714$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11600361$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkV2LGyEUhqVs6Wa3_QvFm_Zu0qPj-AG9CWH7AQvtRXstJ45uLDOajpMl-fd12NBtQY6vx-fVA-8NuUo5eUIogzVjXH_YbLZr0VW9bsHwpha15gDsBVkxMLqRnZFXZAUgZSM0iGtyU8ovqOfOwCtyzZgEaCVbkfB9j9OILvfnhGN0hWLq6Q7d7KfoYo8DrTo-xvlMc6BjPsUw5BO6mGhd_nSo3OjTXMG74vaLax-RujxEWvsxPcQ5ltfkZcCh-DeX_Zb8_HT3Y_uluf_2-et2c984Ic3caOa6HjsdcOcFim6HIjDufQ-et05rpYRkBj3XfRAOUSkju9oPnLM-gGpvycendw_H3eh7VwebcLCHOiNOZ5sx2v9vUtzbh_xoDSi92N9f7FP-ffRltmMszg8DJp-PxSrOjIZ2AfUT6KZcyuTD3y8Y2CUiWyOyoqvaLhEtRdklomp9---Iz8ZLJhV4dwGwOBzChMnF8swJUEwx0f4BbLmgBQ |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1080_09273948_2017_1353103 crossref_primary_10_1016_j_tube_2020_101924 crossref_primary_10_3390_antibiotics11121843 crossref_primary_10_1016_S0140_6736_03_13693_8 crossref_primary_10_1016_j_ijantimicag_2008_08_010 crossref_primary_10_1128_AAC_01637_07 crossref_primary_10_1128_IAI_73_8_4723_4731_2005 crossref_primary_10_1007_s11908_003_0011_0 crossref_primary_10_1128_AAC_02570_12 crossref_primary_10_1586_14787210_2013_839381 crossref_primary_10_1517_14656566_2015_973851 crossref_primary_10_1128_AAC_47_1_138_143_2003 crossref_primary_10_1016_j_ijantimicag_2010_12_007 crossref_primary_10_1586_14787210_2015_1077700 crossref_primary_10_1093_jac_dkp247 crossref_primary_10_1016_j_diagmicrobio_2008_09_003 crossref_primary_10_1016_j_medmal_2009_02_018 crossref_primary_10_1155_2012_436349 crossref_primary_10_1097_01_idc_0000194059_14537_e5 crossref_primary_10_1007_s12028_020_00947_x crossref_primary_10_1007_s40262_013_0062_9 crossref_primary_10_1016_j_tvjl_2005_05_005 crossref_primary_10_1093_jac_dkae098 crossref_primary_10_1016_j_diagmicrobio_2003_10_013 crossref_primary_10_1016_j_idc_2004_04_005 crossref_primary_10_1016_j_idc_2009_06_014 |
| Cites_doi | 10.1086/514622 10.1128/AAC.43.6.1508 10.1093/jac/40.5.639 10.1128/AAC.41.1.101 10.1128/AAC.6.4.437 10.1128/AAC.43.7.1805 10.1128/AAC.41.6.1377 10.1086/516284 10.1128/AAC.42.7.1706 10.1128/am.19.4.573-579.1970 10.1086/514623 10.1128/AAC.37.5.1073 10.1128/AAC.42.6.1397 10.1097/00006454-199011000-00006 10.1001/jama.279.2.125 10.1080/00365549950163590 10.1172/JCI110785 10.1172/JCI107767 10.1128/AAC.17.3.406 |
| ContentType | Journal Article |
| Copyright | 2002 INIST-CNRS Copyright © 2001, American Society for Microbiology 2001 |
| Copyright_xml | – notice: 2002 INIST-CNRS – notice: Copyright © 2001, American Society for Microbiology 2001 |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| DOI | 10.1128/AAC.45.11.3092-3097.2001 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-6596 |
| EndPage | 3097 |
| ExternalDocumentID | 10_1128_AAC_45_11_3092_3097_2001 11600361 14071714 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 .GJ 08R 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ACGFO ADBBV AENEX AFMIJ AGNAY AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 IQODW J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZA5 ZGI ZXP ~A~ AGVNZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
| ID | FETCH-LOGICAL-c469t-81c5da58fabe4a45ba4f12eed0e23c88774619ae28df4caa77965c88f221df073 |
| IEDL.DBID | RPM |
| ISSN | 0066-4804 |
| IngestDate | Tue Sep 17 21:23:46 EDT 2024 Fri Oct 25 05:13:16 EDT 2024 Thu Sep 12 16:51:31 EDT 2024 Sat Sep 28 07:39:20 EDT 2024 Sun Oct 22 16:07:28 EDT 2023 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | Intravenous administration Escherichia coli Rabbit Ceftriaxone Cerebrospinal fluid Moxifloxacin Carbapenem derivatives Fluoroquinolone derivatives Bacteria Meningitis Meropenem Quinolone derivatives Enterobacteriaceae Nervous system diseases β-Lactams Single dose Lagomorpha Biological activity Vertebrata Antibiotic Chemotherapy Cephalosporin derivatives Mammalia Treatment Animal Central nervous system disease Antibacterial agent Pharmacokinetics |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c469t-81c5da58fabe4a45ba4f12eed0e23c88774619ae28df4caa77965c88f221df073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Corresponding author. Mailing address: Department of Pediatrics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9063. Phone: (214) 648-3720. Fax: (214) 648-2961. E-mail: rodriguez_cerrato@yahoo.com. |
| OpenAccessLink | https://europepmc.org/articles/pmc90787?pdf=render |
| PMID | 11600361 |
| PQID | 72198037 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_90787 proquest_miscellaneous_72198037 crossref_primary_10_1128_AAC_45_11_3092_3097_2001 pubmed_primary_11600361 pascalfrancis_primary_14071714 |
| PublicationCentury | 2000 |
| PublicationDate | 2001-11-01 |
| PublicationDateYYYYMMDD | 2001-11-01 |
| PublicationDate_xml | – month: 11 year: 2001 text: 2001-11-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2001 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | 10348784 - Antimicrob Agents Chemother. 1999 Jun;43(6):1508-10 4157341 - Antimicrob Agents Chemother. 1974 Oct;6(4):437-41 4986725 - Appl Microbiol. 1970 Apr;19(4):573-9 6448576 - Antimicrob Agents Chemother. 1980 Mar;17(3):406-11 2263430 - Pediatr Infect Dis J. 1990 Nov;9(11):810-4 4546548 - J Clin Invest. 1974 Aug;54(2):316-25 9174203 - Antimicrob Agents Chemother. 1997 Jun;41(6):1377-9 9440662 - JAMA. 1998 Jan 14;279(2):125-9 9675443 - Clin Infect Dis. 1998 Jul;27(1):10-22 9675446 - Clin Infect Dis. 1998 Jul;27(1):33-9 9455502 - Clin Infect Dis. 1998 Jan;26(1):1-10; quiz 11-2 9421311 - J Antimicrob Chemother. 1997 Nov;40(5):639-51 6826714 - J Clin Invest. 1983 Mar;71(3):411-9 8517694 - Antimicrob Agents Chemother. 1993 May;37(5):1073-81 9661008 - Antimicrob Agents Chemother. 1998 Jul;42(7):1706-12 10482059 - Scand J Infect Dis. 1999;31(3):287-91 8980763 - Antimicrob Agents Chemother. 1997 Jan;41(1):101-6 9624483 - Antimicrob Agents Chemother. 1998 Jun;42(6):1397-407 10390250 - Antimicrob Agents Chemother. 1999 Jul;43(7):1805-7 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_20_2 e_1_3_2_10_2 e_1_3_2_21_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_22_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_2_2 e_1_3_2_14_2 |
| References_xml | – ident: e_1_3_2_20_2 doi: 10.1086/514622 – ident: e_1_3_2_21_2 doi: 10.1128/AAC.43.6.1508 – ident: e_1_3_2_2_2 doi: 10.1093/jac/40.5.639 – ident: e_1_3_2_22_2 doi: 10.1128/AAC.41.1.101 – ident: e_1_3_2_5_2 doi: 10.1128/AAC.6.4.437 – ident: e_1_3_2_11_2 doi: 10.1128/AAC.43.7.1805 – ident: e_1_3_2_3_2 doi: 10.1128/AAC.41.6.1377 – ident: e_1_3_2_4_2 doi: 10.1086/516284 – ident: e_1_3_2_12_2 – ident: e_1_3_2_13_2 doi: 10.1128/AAC.42.7.1706 – ident: e_1_3_2_18_2 doi: 10.1128/am.19.4.573-579.1970 – ident: e_1_3_2_10_2 doi: 10.1086/514623 – ident: e_1_3_2_6_2 doi: 10.1128/AAC.37.5.1073 – ident: e_1_3_2_17_2 doi: 10.1128/AAC.42.6.1397 – ident: e_1_3_2_9_2 doi: 10.1097/00006454-199011000-00006 – ident: e_1_3_2_14_2 doi: 10.1001/jama.279.2.125 – ident: e_1_3_2_8_2 doi: 10.1080/00365549950163590 – ident: e_1_3_2_16_2 doi: 10.1172/JCI110785 – ident: e_1_3_2_19_2 doi: 10.1172/JCI107767 – ident: e_1_3_2_7_2 – ident: e_1_3_2_15_2 doi: 10.1128/AAC.17.3.406 |
| SSID | ssj0006590 |
| Score | 1.8872682 |
| Snippet | Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this... ABSTRACT Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The... Moxifloxacin, an 8-methoxyquinolone with broad-spectrum activity in vitro, was studied in the rabbit model of Escherichia coli meningitis. The purposes of this... |
| SourceID | pubmedcentral proquest crossref pubmed pascalfrancis |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 3092 |
| SubjectTerms | Animals Anti-Infective Agents - cerebrospinal fluid Anti-Infective Agents - pharmacokinetics Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Area Under Curve Aza Compounds Biological and medical sciences Ceftriaxone - therapeutic use Cephalosporins - therapeutic use Escherichia coli - drug effects Experimental Therapeutics Fluoroquinolones Male Medical sciences Meningitis, Escherichia coli - cerebrospinal fluid Meningitis, Escherichia coli - drug therapy Meningitis, Escherichia coli - microbiology Microbial Sensitivity Tests Pharmacology. Drug treatments Quinolines Rabbits Thienamycins - therapeutic use |
| Title | Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/11600361 https://search.proquest.com/docview/72198037 https://pubmed.ncbi.nlm.nih.gov/PMC90787 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-WwsZgjC37Srdlehh9qhN_SJb8mIWUsuGRQQt9M7I-qKG1w5xC89_3ZNlLM_Y0MMJfkozvrNPPursfwFeJSqAMV4E2oQvJSVlQpqEOcO5sQpWmIVcudjj_mZ5f0u9X7KqP4257t8paldWsvrmd1dV151u5uVXzwU9svs6XCOgEn49ghOo5APR-8E2Z_62CljSgIqSD804s5ovFckYZ7s-SMIsDLLjDhx1XTJS6xCzRgXF6sZEtvifrCS7-NQP925HykWU6ewUv-yklWfhHfw1PTD2Gp55kcjeGZ3m_fD6Gk7VPVL07JRf7uKv2lJyQ9T6F9e4N2OFQe8L6lshak28-s7OqtOtOed4J0liSN_eVvWnuJXZDcFs9og0gq9bpReV8qgm2X5HceJakqn0Ll2eri-V50DMyBAph9DYQkWJaMmFlaaikrJTURjGa2dDEicLxilMEZNLEQluqpOQ8Sxmet3EcaYujyTs4qpvafACiuTVZjJZRa0qtkqJMtE4SVmaSKyvoBKJBFMXGJ94oOsASiwIlWVCG-4WTpCu4o9OMJjA9kNm-YgdbI2z0yyDEAj8jtzYia9PctQUC4UyECZ_Aey_Sfd1eNybADoT95waXoPvwCuptl6i709Pj_6z3EZ53_m5d3OMnONr-vjOfcQK0Lacw-vFLTDvFfwAPYwcX |
| link.rule.ids | 230,315,730,783,787,888,27936,27937,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFD5sHbvA2CXdJbu0ehh9qh1fJMt5zEJKttUlDyn0zci6MLPGCXMCzX79jix7acpeNjBCtm7I_qRzjnUuAJ8EgkBqLj2lA2uSkzCvSALlIe-sA5kkAZfWdji7SKaX9OsVu2rtuOtWrbKSRelX1wu_Kr83upWrhRx0emKDWTZGgS7lg_vwAFdrQDsRvd1-E-Z-rCAt9SgWd-o7UToYjcY-ZZj342AYeZhwKyE20WLCxLpmCffI09OVqPFNGRfi4m886F1Vylu06ew5zLtZOZWUH_5mXfjy1x2Hj_847RfwrOVVycgVvoR7uurBQxe9ctuDR1l7Lt-Dk5nzgL09JfOdQVd9Sk7IbOcbe3sIprtV20ossAoRlSKfnctoWSo7nHQBLcjSkGx5U5rr5Y3AYQhek1vxCMiktoArrbI2wf5LkmkXfqmsX8Hl2WQ-nnptqAdPony-9tJQMiVYakShqaCsENSEEdLvQEexxI2QU5T0hI5SZagUgvNhwvC5iaJQGdymXsNBtaz0WyCKGz2MkOQqRamRIi1ipeKYFUPBpUlpH8LuC-cr59EjbyShKM0RIDllmM8tQGzCbZzOsA9He1DYNWzk4RA7Pe6wkeP6tIcuotLLTZ2jhD1Mg5j34Y1Dyq5tC7k-sD0M_algPX_vlyAyGg_gDRLe_We7Y3g8nWfn-fmXi2_v4UmjVNcYV36Ag_XPjf6IXNa6OGpW1W8Rsie1 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZbx8pg7JJ1W3Zp9TD6VN8lS37MsoTukpKHFvJmZF2YWWOHOYFmv35Hlr00ZU8FI2RbF2R_0jlHOheEPgkAgdRMekqH1iQnpV6RhsoD3lmHMk1DJq3t8OwiPb8i3xZ00W1dNJ1aZSWL0q-ul35V_mx1K1dLGfR6YsF8NgaBjrNgpUzwED2CGRumvZjeLcEpdZsrQE89wkPSq_DEPBiNxj6hkPeTMIs9SJiVEtuIMVFq3bNEeyTq6Uo08LWMC3PxPz70rjrlLfo0fY4W_cicWsovf7MufPnnjtPHewz9BXrW8ax45Aq8RA90NUCPXRTL7QAdzrrz-QE6nTtP2NszfLkz7GrO8Cme73xkb18h09-qbSWWUASLSuHPznW0LJXtTrrAFrg2eFbflOa6vhHQDYZrcisuAZ40FnilVdrG0H6JZ9qFYSqbI3Q1nVyOz70u5IMnQU5fezySVAnKjSg0EYQWgpgoBjoe6jiRsCAyAhKf0DFXhkghGMtSCs9NHEfKwHL1Gh1UdaXfIqyY0VkMpFcpQowUvEiUShJaZIJJw8kQRf1fzlfOs0feSkQxzwEkOaGQzy1IbMJsvM5oiI734LCr2MrFETR60uMjh3lqD19EpetNk4OknfEwYUP0xqFlV7eD3RDRPRz9K2A9gO-_AXS0nsBbNLy7Z70TdDj_Ms1_fL34_h49aXXrWhvLD-hg_XujPwKztS6O24n1Fz96KjU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacodynamics+and+bactericidal+activity+of+moxifloxacin+in+experimental+Escherichia+coli+meningitis&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Rodriguez-Cerrato%2C+V&rft.au=McCoig%2C+C+C&rft.au=Michelow%2C+I+C&rft.au=Ghaffar%2C+F&rft.date=2001-11-01&rft.issn=0066-4804&rft.volume=45&rft.issue=11&rft.spage=3092&rft.epage=3097&rft_id=info:doi/10.1128%2FAAC.45.11.3092-3097.2001&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |